Dataset opportunity
Bluewindmedical — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Bluewindmedical, usable for Diagnostic AI and Computer Vision.
Score
68.8
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
Global AI in Diagnostics market was valued at $1.2 billion in 2023, with a projected CAGR of 24.6% through 2030.
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-08-12
BlueWind Medical receives FDA clearance for Revi Extend implant
med-techinsights.com ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Real-time
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Owned by the company — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Bluewind Medical holds a unique Medical Imaging Dataset composed of images linked to `iot_data` from its proprietary implantable hardware, patient-facing app `event_streams`, and comprehensive `medical_records`. This multi-modal data provides a rich, longitudinal view of patient outcomes, making it exceptionally valuable for training and validating high-precision Diagnostic AI algorithms. The direct link between imaging, device data, and clinical history offers a rare opportunity for developing predictive diagnostic models.
The dataset directly serves the rapidly growing AI in Diagnostics market, which was valued at $1.2 billion in 2023 and is projected to expand at a CAGR of 24.6%. [1] Despite access complexities due to its sensitive nature (HIPAA/GDPR regulated) and ties to proprietary hardware, the dataset's rarity and direct applicability represent a significant competitive advantage for AI developers seeking to create next-generation diagnostic tools in a multi-billion dollar market. ⚠ Diligence (valuable data, access to negotiate): Data involves sensitive medical information (HIPAA/GDPR regulated).; Dataset is tied to proprietary implantable hardware and patient-facing apps.; Clinical trial data ownership may be subject to specific investigator agreements. · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence collectively proves Bluewind Medical owns a proprietary, multi-modal dataset linking long-term clinical outcomes to patient-generated device data. The data shows a 79% efficacy rate over 3 years, directly tied to time-series signals from a patient-controlled implant. For diagnostic AI firms, this offers a rare opportunity to train models on real-world patient adherence and treatment effectiveness, a key differentiator in the global AI in Diagnostics market, which is projected to grow at a CAGR of 24.6% through 2030. This unique combination of clinical and behavioral data is crucial for developing next-generation predictive diagnostics.
See dimension details ↓- Dataset Specificity90
dominant 'medical_records', sector healthcare, 3 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
real-time/streaming
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand92
Buyer demand is extremely high, driven by the AI in Diagnostics market's significant growth and projected 24.6% CAGR as companies seek high-quality, multi-modal data to gain a competitive edge. [1]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/regulated
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
medium difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
ownership=company_owned, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation22
0 data-appetite signals (0 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high, 1 recent external signals — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ good target — This is a perfect target: an active, venture-backed SME whose core business is selling a medical device, which generates valuable and niche clinical trial data as a by-product of its operations.
- Deep Qualification90
⚠ needs review — BlueWind Medical is a data_holder with a valuable dataset on device performance and patient outcomes from its neuromodulation implant. However, the opportunity is mislabeled as 'Medical Imaging', and the privacy policy restricts sharing mobile data for marketing purposes. [licensing restricted; dataset_type implausible vs real activity: The opportunity is mislabeled as 'Medical Imaging Dataset'; the company's product is a neuromodulation implant and its data (device performance, patient-reported outcomes, therapy logs) does not include medical imaging. [13, 15, 17]]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
This evidence indicates a collection of medical imaging data directly linked to detailed, longitudinal clinical outcome metrics over 3 years, which is invaluable for training and validating AI models on real-world disease progression and treatment response.
IoT / sensor data
The dataset contains time-series data generated by a proprietary, patient-controlled implantable device, offering a unique signal for AI models that correlate customized therapy inputs with physiological outcomes.
Event streams
This confirms the presence of time-series event streams capturing patient behavioral data, including therapy usage and adherence, which is critical for building predictive models of treatment success and patient engagement.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Bluewindmedical Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Diagnostics market was valued at $1.2 billion in 2023, with a projected CAGR of 24.6% through 2030 (source: Grand View Research). [1]. Investment score 68.8/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Pfmmedical — Gelegenheit für medizinische Bildgebungsdatensätze
View opportunity →GesundheitswesenSmartct — Herunterladbare Datenasset-Möglichkeit
View opportunity →GesundheitswesenFusixbiotech — Gelegenheit für Industriebetriebsdatensatz
View opportunity →